Literature DB >> 19644885

Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells.

Maija-Leena Eloranta1, Tanja Lövgren, Doreen Finke, Linda Mathsson, Johan Rönnelid, Berthold Kastner, Gunnar V Alm, Lars Rönnblom.   

Abstract

OBJECTIVE: Interferon-alpha (IFNalpha) is produced in several autoimmune diseases, including systemic lupus erythematosus (SLE), and may be important in their pathogenesis. We undertook this study to investigate how IFNalpha production induced by RNA-containing immune complexes (ICs) in plasmacytoid dendritic cells (PDCs) is regulated.
METHODS: Normal PDCs purified from peripheral blood mononuclear cells (PBMCs) were cocultivated with other cell populations isolated from healthy individuals or SLE patients. IFNalpha production was induced by RNA-containing ICs, which consisted of anti-RNP autoantibodies and U1 small nuclear RNP particles, and the effects of prostaglandin E2 (PGE2), reactive oxygen species (ROS), or the cytokines IFNalpha2b, granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-10 (IL-10), or tumor necrosis factor alpha (TNFalpha) were explored.
RESULTS: Monocytes inhibited IFNalpha production by PDCs in PBMC cultures, while natural killer (NK) cells were stimulatory. The monocytes had little effect on IFNalpha production by pure PDCs but inhibited its stimulation by NK cells. Monocytes from SLE patients were less inhibitory. Exposure of PBMCs or PDCs to IFNalpha2b/GM-CSF increased their IFNalpha production. RNA-containing ICs caused production of ROS, PGE2, and TNFalpha, especially in monocytes. These mediators and IL-10 suppressed IFNalpha production in PBMC cultures, with ROS and PGE2 also inhibiting IFNalpha production by purified PDCs. Inhibition by all of these agents, except for ROS, was abolished by IFNalpha2b/GM-CSF. The inhibitory effect of monocytes was significantly counteracted by the ROS scavengers serotonin and catalase.
CONCLUSION: IFNalpha production induced by RNA-containing ICs in PDCs is regulated by a network of interactions between monocytes, NK cells, and PDCs, involving several pro- and antiinflammatory molecules. This should be considered when designing and applying new therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19644885     DOI: 10.1002/art.24686

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  40 in total

Review 1.  Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases.

Authors:  Jing Li; Xiaohui Wang; Fengchun Zhang; Hang Yin
Journal:  Pharmacol Ther       Date:  2013-03-24       Impact factor: 12.310

Review 2.  Dendritic cells in systemic lupus erythematosus.

Authors:  Heather M Seitz; Glenn K Matsushima
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

3.  Antigen is required for maturation and activation of pathogenic anti-DNA antibodies and systemic inflammation.

Authors:  Jeganathan Venkatesh; Hajime Yoshifuji; Daisuke Kawabata; Prameladevi Chinnasamy; Anfisa Stanevsky; Christine M Grimaldi; Joel Cohen-Solal; Betty Diamond
Journal:  J Immunol       Date:  2011-03-28       Impact factor: 5.422

Review 4.  The Role of Damage-Associated Molecular Patterns in Human Diseases: Part I - Promoting inflammation and immunity.

Authors:  Walter G Land
Journal:  Sultan Qaboos Univ Med J       Date:  2015-01-21

Review 5.  Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?

Authors:  Ismael Calero; Iñaki Sanz
Journal:  Discov Med       Date:  2010-11       Impact factor: 2.970

Review 6.  Type I interferon and systemic lupus erythematosus.

Authors:  Keith B Elkon; Vivian V Stone
Journal:  J Interferon Cytokine Res       Date:  2011-08-22       Impact factor: 2.607

7.  C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes.

Authors:  Deanna M Santer; Brian E Hall; Thaddeus C George; Stephanie Tangsombatvisit; Chih Long Liu; Peter D Arkwright; Keith B Elkon
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

8.  Serum level of DNase1l3 in patients with dermatomyositis/polymyositis, systemic lupus erythematosus and rheumatoid arthritis, and its association with disease activity.

Authors:  Qi Zhao; Chunshu Yang; Jianing Wang; Yujia Li; Pingting Yang
Journal:  Clin Exp Med       Date:  2016-12-30       Impact factor: 3.984

9.  Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus.

Authors:  Gina S Garcia-Romo; Simone Caielli; Barbara Vega; John Connolly; Florence Allantaz; Zhaohui Xu; Marilynn Punaro; Jeanine Baisch; Cristiana Guiducci; Robert L Coffman; Franck J Barrat; Jacques Banchereau; Virginia Pascual
Journal:  Sci Transl Med       Date:  2011-03-09       Impact factor: 17.956

Review 10.  Fueling autoimmunity: type I interferon in autoimmune diseases.

Authors:  Jeremy Di Domizio; Wei Cao
Journal:  Expert Rev Clin Immunol       Date:  2013-03       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.